Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The outer membrane of Gram-negative bacteria acts as a formidable permeability barrier, protecting the cell from environmental stressors and many antibiotics (Nikaido, 2003). This structural integrity is largely maintained by the presence of divalent cations, specifically magnesium (Mg2+) and calcium (Ca2+), which form essential cross-bridges between negatively charged phosphate groups on lipopolysaccharides (LPS) and phospholipids (Clifton et al., 2015). These ionic interactions neutralize electrostatic repulsion between anionic lipid heads, effectively 'zipping' the membrane components together to create a dense, stable leaflet (Hancock, 1997). Disruption of these cation bridges is a primary mechanism for several classes of antibiotics, most notably the polymyxins, such as colistin and polymyxin B (Trimble et al., 2016). These cationic drugs possess a higher affinity for the lipid phosphate groups than the native divalent cations, allowing them to competitively displace the ions and destabilize the membrane (Moore et al., 1986). This displacement leads to increased membrane permeability, a phenomenon termed 'self-promoted uptake,' which facilitates the drug's entry and eventual disruption of the cytoplasmic membrane (Hancock, 1984). Targeting these cross-bridges is a critical strategy for treating multidrug-resistant infections caused by pathogens such as Pseudomonas aeruginosa and Acinetobacter baumannii (Trimble et al., 2016). However, therapeutic use is often limited by the potential for nephrotoxicity and the emergence of resistance mechanisms, such as the mcr-1 gene, which modifies the anionic target sites to reduce drug binding (Liu et al., 2016).
Competitive displacement of divalent cations (Mg2+, Ca2+) from phosphate groups of the outer membrane, leading to membrane disruption and self-promoted uptake.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gram-negative bacterial outer membrane phospholipids and divalent cation cross-bridges.